Last reviewed · How we verify

NCT05530915

Guayusa: The Effect of an Herbal Extract on Alertness and Mental Fatigue

Completed NA Last updated 14 November 2022
What this trial tests

NA trial testing Gel capsule in Attention Difficulties in 60 participants. Completed in 7 November 2022.

Timeline
27 July 2022
Primary endpoint
7 November 2022
7 November 2022

Quick facts

Lead sponsorPepsiCo Global R&D
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposebasic science
Enrollment60
Start date27 July 2022
Primary completion7 November 2022
Estimated completion7 November 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

PepsiCo Global R&D — full company profile →

Who can join

Adults 18 to 55, any sex, with Attention Difficulties. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this randomized, double-blind, placebo-controlled, cross-over study is to assess the acute effects of a novel ingredient, guayusa on alertness and mental fatigue compared to a placebo. This trial will utilize the COMPASS cognitive task and cognitive demand battery (CDB) and mood, motivation, and energy measures with assessments taking place at baseline, 60- and 120-minutes post treatment on three separate testing days separated by \~7 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Attention Difficulties

Currently open trials in the same condition.

Other PepsiCo Global R&D trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05530915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing